Not available in the U.S.
Flucloxacillin
FLOXAPEN
What it isA penicillinase-resistant isoxazolyl penicillin that inhibits bacterial cell-wall synthesis and resists staphylococcal beta-lactamase.
Why this oneA first-line anti-staphylococcal penicillin for MSSA infections in the UK, Europe, and Australia, analogous to U.S. dicloxacillin and nafcillin.
What limits itIt is not available in the U.S. and carries a notable risk of delayed cholestatic hepatitis strongly associated with the HLA-B*57:01 allele.
NO BOXED WARNINGS
Principal riskNot FDA-approved (not marketed in the U.S.), so no FDA boxed warning.
Classes and tags
Clinical profile
Mechanism of action: Flucloxacillin ballicule
